Bloodlet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bloodlet

What is Bloodlet? (Leucovorin Calcium)

Property Description
Active ingredient Leucovorin Calcium (Folinic Acid)
Form Oral Tablet, Injection/Infusion Solution
Pharmacological class Reduced Folate Derivative, Antidote
General purpose Chemoprotection / Rescue Therapy
Origin Synthetic Compound

Bloodlet is the trade name for the prescription-only medicine containing Leucovorin Calcium, a chemically prepared compound classified as a reduced folate derivative. It is defined by its core pharmacological role as an essential antidote and chemoprotectant, serving as an adjunctive therapy agent that supports the body during powerful medical treatments.

What Type of Medicine is Bloodlet (Leucovorin Calcium)?

Leucovorin Calcium is a synthetic analogue of folinic acid, an active form of the essential B vitamin, folic acid. It is pharmacologically classified as a Folate Analog. The clinical differentiation of Leucovorin from standard folic acid is its pre-reduced, biologically active state, which ensures immediate availability for critical cellular functions. The active ingredient, Leucovorin, is supplied as the stable Calcium salt of folinic acid. As a single-ingredient product, it is manufactured in various preparations, including oral tablets and an aqueous solution for injection/infusion (parenteral administration).

General Purpose: Why is Leucovorin Referred to as a Rescue Agent?

The general purpose of Leucovorin is to protect healthy, rapidly dividing cells from the unintended harm of anti-folate therapies. Its therapeutic benefit is derived from its ability to immediately replenish essential tetrahydrofolate co-factors, which are vital for fundamental cellular repair and replication. By supplying this active folate, Leucovorin helps shield susceptible tissues, such as bone marrow and the gastrointestinal lining, from toxicity, fulfilling its critical role as a protective rescue agent during intensive treatments.

Regulatory References

  1. National Cancer Institute (NCI)

What side effects are possible with Bloodlet?

Possible Side Effects and Safety Information

The officially documented adverse effects for Bloodlet (Leucovorin Calcium) are generally associated with uncommon or rare frequency when the medicine is administered alone. The most frequently cited reactions are classified within a small number of System-Organ Classes (SOCs), which include Immune System Disorders and the Nervous System Disorders.


Adverse Reactions and Frequency Classification

Adverse reactions directly attributed to Leucovorin Calcium are generally infrequent:

  • Uncommon (occurring in fewer than 1 in 100 patients): Allergic reactions, including hypersensitivity and urticaria (hives), and fever following parenteral administration.
  • Rare (occurring in fewer than 1 in 1,000 patients): Psychiatric Disorders (insomnia, agitation, depression) and Nervous System effects such as seizures/convulsions and syncope (fainting).

Safety Considerations and Restrictions

The safety profile is heavily defined by its context of use and specific regulatory constraints:

  • Combination Toxicity: When used alongside 5-fluorouracil, Leucovorin significantly enhances the toxicity of the chemotherapy agent, potentially leading to severe, life-threatening gastrointestinal damage (e.g., severe diarrhea, stomatitis) and myelosuppression.
  • Serious Adverse Reactions: Rare but serious reactions include anaphylactoid reactions and seizures, particularly associated with high intravenous doses. Fatal outcomes have been reported following the inappropriate intrathecal (spinal) administration of Leucovorin, which is strictly contraindicated.
  • Population-Specific Notes: Safety documents note that elderly patients are at an increased risk of severe gastrointestinal toxicity in combination therapy. Leucovorin is also contraindicated for treating megaloblastic anemia due to Vitamin B12 deficiency, as it may mask the condition while neurological damage progresses.

Overdose and Emergency Response

Overdose and When to Seek Help

The official profile for Bloodlet (Leucovorin Calcium) overdose centers on two primary risks and mandatory emergency actions as outlined in regulatory documentation.


Overdose Manifestations and Severity

An overdose of Leucovorin Calcium alone may nullify the desired effect of concurrently administered folic acid antagonists. However, the most severe manifestations occur when Leucovorin is used with agents like 5-fluorouracil (5-FU), where toxicity is enhanced, leading to documented leucopenia, stomatitis, and life-threatening severe diarrhea and enterocolitis. Regulatory documents confirm that death has been reported in association with this severe gastrointestinal toxicity, particularly in elderly patients. Furthermore, regulatory warnings state that intrathecal administration of Leucovorin after an intrathecal methotrexate overdose has also resulted in death.


Immediate Emergency Action

Overdose of a folate antagonist requiring rescue should be treated as a medical emergency requiring immediate medical attention. Prompt administration is essential for effectiveness. Official protocol requires close monitoring of fluid and electrolyte status and specific laboratory markers, including serum creatinine and serum methotrexate concentrations, determined daily. Supportive measures detailed in official labeling include continuous hydration and achieving urinary alkalinization. Contact the regional poison control centre immediately in the event of a suspected overdose.

Therapeutic Uses of Bloodlet

What Bloodlet Treats: Main Uses and Benefits

Bloodlet (Leucovorin Calcium) is generally used in situations involving certain distressing symptoms primarily across three therapeutic areas. It is commonly applied as a rescue agent to mitigate the severe systemic toxic effects of high-dose chemotherapy regimens, such as for osteosarcoma. It is also an adjunctive agent for advanced colorectal cancer and is applied as an antidote for inadvertent overdosage of folic acid antagonists. Furthermore, it is considered relevant in the management of specific conditions like megaloblastic anemia and rare neurological disorders like Cerebral Folate Deficiency (CFD).

This medication contributes to easing the overall symptom load and is relevant in contexts involving heightened systemic burden that involve acute or unstable symptom patterns. This supportive therapy helps patients cope more steadily with difficult episodes and is relevant for managing symptoms that interfere with daily comfort.

Quick Fact: Relief for Toxic Systemic Strain

Quick Fact: Relief for Toxic Systemic Strain Bloodlet's primary use helps mitigate severe myelosuppression and gastrointestinal damage, which are two of the most disruptive symptoms related to high-intensity anti-folate therapies. Its use assists with maintaining functional stability during these periods of acute physiological stress.

Regulatory References

  1. National Cancer Institute (NCI) overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Bloodlet

The eligibility profile for Bloodlet (Leucovorin Calcium) is defined by specific exclusions and conditions detailed in official regulatory documents.

Category Eligibility Classification
Contraindicated Populations Patients with Pernicious Anemia or other megaloblastic anemias caused by Vitamin B12 deficiency must not use this medicine.
Administration Exclusion Intrathecal administration (injection into the spinal fluid) is contraindicated and may be harmful.
Hypersensitivity Use is contraindicated for patients with a known hypersensitivity to any component of the formulation.

Conditional Eligibility Rules

  • Age-Related Risk: Older adults using the medicine in combination with 5-fluorouracil are at a greater risk of severe gastrointestinal toxicity.
  • Organ Function: Conditional use is specified for patients with renal insufficiency or third space fluid accumulation, who may require adjustments due to delayed elimination.
  • Pediatric Use: The medicine may increase seizure frequency in susceptible pediatric patients; some agencies note the indication for pediatric use is not authorized.
  • Pregnancy Status: Use is classified as Pregnancy Category C and should only occur if clearly needed. Caution is advised for nursing mothers.

Connection to the overall eligibility profile

The official labeling establishes strict boundaries for use based on absolute exclusions (B12 deficiency/hypersensitivity) and conditional use related to physiological states (renal function) and concomitant drug use, guiding appropriate patient selection.

What should I know about interactions with other medicines?

Bloodlet (Leucovorin Calcium) has officially documented interactions primarily related to its function as a reduced folate, which structure its use with other powerful medicinal products.

Drug–Drug Interactions

Co-administration with Folic Acid Antagonists, such as Methotrexate, Trimethoprim, and Pyrimethamine, can result in pharmacodynamic antagonism, where the intended effect of the anti-folate medicine is counteracted. Regulatory documents state that an excessive amount of Leucovorin may formally nullify the chemotherapeutic effect of these agents.

Conversely, Leucovorin is documented to enhance the cytotoxicity and toxicity of certain antimetabolites. The combination with 5-Fluorouracil (5-FU) is associated with an increased risk for severe gastrointestinal toxicities, including diarrhea and stomatitis. Regulatory labeling notes that elderly or debilitated patients are at a greater risk for this specific combination toxicity.

A separate interaction involves antiepileptic substances like Phenobarbital, Phenytoin, and Primidone. Regulatory information states that Leucovorin may decrease the plasma concentrations of these medicines, which is associated with an increased frequency of seizures.

Restrictions and Procedural Constraints

A procedural restriction mandates that Leucovorin must not be mixed with 5-Fluorouracil in the same intravenous injection or infusion due to the potential formation of a precipitate. Furthermore, Leucovorin is formally contraindicated for the therapy of megaloblastic anemias caused by Vitamin B12 deficiency, as this may allow severe neurological damage to progress while hematologic signs are obscured.

Mechanism of Action

How Bloodlet Works — Mechanism of Action


Functional Antagonism: Bypassing Metabolic Blockade

The mechanism of Leucovorin Calcium involves the delivery of ready-to-use tetrahydrofolate (THF) co-factors, which enter the cell via the Reduced Folate Carrier (RFC). This action allows the cell's metabolic machinery to functionally bypass the enzyme blockade caused by antifolate agents (like those targeting DHFR). The immediate restoration of the essential co-factor pool mitigates metabolic interference in healthy, rapidly dividing tissues, which sustains the operation of fundamental synthesis pathways.


Restoration of Nucleotide Synthesis

By providing the THF co-factors, Leucovorin sustains the one-carbon transfer reactions vital for the de novo synthesis of purine nucleotides and deoxythymidylate (dTMP). This metabolic restoration is a key physiological consequence, as it avoids severe nucleotide depletion and sustains the molecular requirements for DNA replication and repair in susceptible cell lines.


Mechanistic Potentiation of Enzyme Inhibition

In a distinct mechanistic application, Leucovorin acts as a mechanistic modulator rather than an antagonist. The active metabolite, 5,10-methylenetetrahydrofolate, works as an essential co-factor that significantly stabilizes the inhibitory complex formed between fluoropyrimidine metabolites and the Thymidylate Synthase (TS) enzyme. This results in a prolonged and intensified blockade of the TS enzyme, increasing metabolic disruption.

Dosage and Administration Information

Bloodlet (Leucovorin Calcium) is administered in a highly structured and context-dependent manner, where the dose, frequency, and route are determined by the specific therapeutic regimen being supported. The medicine is supplied as oral tablets (5 mg to 25 mg strengths) and as an injection solution for both intravenous (IV) and intramuscular (IM) use.

For its primary role as a supportive rescue agent, administration is time-critical. The initial dose must be given 24 hours after the start of the primary drug. The standard regimen is 15 mg every 6 hours (q6h). However, if laboratory tests indicate delayed elimination (e.g., due to impaired renal function), the dose and frequency are escalated immediately, potentially up to 150 mg IV every 3 hours (q3h).

The administration is highly conditional and requires procedural control. Oral administration is not suitable for single doses greater than 25 mg or in the presence of gastrointestinal toxicity; the parenteral route is specified in these scenarios. For injection, the solution must be diluted with 5% Dextrose or Normal Saline, and the IV injection rate must not exceed 160 mg per minute. Furthermore, the medicine is strictly forbidden for intrathecal administration. The treatment course is maintained until serum drug levels fall below a specific threshold (e.g., 0.05 µM).

Recent Clinical Evidence

Research Evidence Overview

The available research base for Bloodlet (Leucovorin Calcium) is derived primarily from Randomized Controlled Trials (RCTs), large-scale meta-analyses, and systematic reviews exploring its role across defined clinical situations. This overview summarizes the structure of those studies, the types of findings reported, and what remains uncertain.

Chemoprotection and Rescue Agent

Bloodlet was studied for use in acute toxicities linked to high-dose anti-folate chemotherapy, such as Methotrexate. Researchers examined these uses in numerous studies, including RCTs on pediatric and adult patients. Outcomes monitored included the clearance rate of the chemotherapy drug, hematological biomarkers (like blood cell counts), and measurements of acute discomfort outcomes. Findings describe patterns observed in the studies related to outcomes measured during the acute phases of these toxicities. Consistency remains an area of active discussion across research groups attempting to refine specific rescue protocols within complex combination therapies.

Adjunctive Therapy and Rare Conditions

Bloodlet was studied for use as an adjunctive agent in advanced colorectal cancer. This use was evaluated in multiple large-scale RCTs and meta-analyses that monitored long-term measurements, including Overall Survival and Progression-Free Survival. Reported outcomes involved comparisons of progression rates observed between study groups. Additionally, Bloodlet was studied for use in specific, rare conditions, such as Cerebral Folate Deficiency (CFD), primarily in pediatric patients. The evidence quality varies across studies for these rare conditions, and sample sizes were modest in controlled studies.

Research Limitations and Uncertainty

Key limitations in the overall evidence include inconsistent results reported across various studies when comparing different combination regimens. For many applications, certainty remains low regarding the superiority of all combination protocols over all single-agent approaches. Long-term outcomes and data for certain patient groups remain subject to ongoing scientific exploration.

Key Studies & References

  1. Approval of Previously Withdrawn New Drug Application for WELLCOVORIN (leucovorin calcium) Tablets - Federal Register Notice
  2. Cerebral Folate Deficiency, Folate Receptor Alpha Autoantibodies and Leucovorin: A Systematic Review and Meta-Analysis (Scientific Literature)
  3. Leucovorin Calcium - National Cancer Institute Drug Dictionary Entry

Frequently Asked Questions (FAQ)

Common questions about Bloodlet (FAQ)


Q: How quickly can I expect Bloodlet to start working?

A: Official drug information describes how quickly the medicine becomes active in the body. After administration, the active compound is rapidly converted into the main active substance. Official data describes that, for oral use, the highest levels of the active reduced folates in the blood are generally reached within two to three hours.

Q: Does Bloodlet have a generic version available?

A: Yes, Bloodlet is a brand name for a prescription medicine. Regulatory documents confirm that the active ingredient, Leucovorin Calcium, is widely available under its generic name, in addition to being sold under various brand names.

Q: How does Bloodlet interact with common over-the-counter pain relievers?

A: Official safety information often advises patients to confirm the use of any over-the-counter (OTC) pain relievers with their treating physician. This is because certain common OTC medicines, such as Ibuprofen or Aspirin, have the potential to increase the chance of bleeding risk, especially within complex treatment protocols.

Q: Can vitamins and supplements interfere with Bloodlet?

A: While official labeling primarily lists interactions with other prescription medications, general safety guidance cautions that all substances, including vitamins and dietary supplements, should be reviewed by a healthcare professional. This precaution is advised because supplements could potentially affect how the medicine works or its overall safety profile.

Q: Are there any specific foods or drinks that should be avoided with Bloodlet?

A: There are generally no specific foods or drinks listed as drug interactions in official documents. However, some regulatory guidance suggests taking the oral tablets with water on an empty stomach to support absorption.

Q: Is Bloodlet safe to use if I have a history of liver problems?

A: The safety profile of Bloodlet itself does not have a primary contraindication specific to liver impairment. However, because this medicine is often used as supportive therapy alongside powerful chemotherapy agents, official safety guidance emphasizes the importance of informing the treating physician about any history of liver issues.

Q: Can men and women use Bloodlet for the same reasons?

A: Yes, according to official regulatory documentation, the approved uses (indications) for Leucovorin Calcium are based strictly on the medical condition or therapeutic regimen it supports. These indications are not defined or differentiated based on the sex of the patient.

Q: How long does Bloodlet stay in the system after the last use?

A: The time the medicine takes to be eliminated from the body is measured using a value called the terminal half-life. Official pharmacokinetic data indicates that the main active substance has a terminal half-life of approximately 5.7 to 6.2 hours, depending on the route of administration. This figure represents the time it takes for half of the drug to be eliminated.

Q: Is it normal to feel a change in energy levels after starting Bloodlet?

A: The official safety profile does not list general changes in energy levels as a common reaction. The safety profile does not list general changes in energy levels, but other reactions such as fatigue or a general feeling of discomfort are mentioned in regulatory sources.

Q: What is the connection between Bloodlet and heart function?

A: Although not a direct effect in standard use, official documents for some related high-dose injectable formulations contain warnings associated with the medicine's calcium content. This warning addresses the potential for administering the medicine too quickly, which could be associated with high calcium levels in the blood, potentially affecting heart function.

Q: What is the purpose of the inactive ingredients in Bloodlet?

A: Regulatory labels list all the inactive ingredients used in the product’s specific formulation, such as various salts or compounds like lactose. These substances are included for technical reasons, such as to stabilize the tablet, bind the active drug, or act as a preservative, rather than contributing to the medical effect.

Q: Can Bloodlet affect fertility or hormone levels?

A: Specific effects on general fertility or hormone levels are not extensively detailed in official labeling. However, regulatory documents state that the medicine should be used with caution during pregnancy and by nursing mothers, which suggests potential considerations for reproductive health.

Q: Are there restrictions on mixing Bloodlet with alcohol?

A: Official drug safety information often includes a general caution against the use of alcohol during treatment. This is because alcohol consumption may increase certain side effects and potentially interfere with the effectiveness of the primary therapy that Bloodlet is supporting.

Q: Is it okay to use Bloodlet during cold or flu season with other common remedies?

A: Regulatory information advises that patients check with their healthcare team before taking any over-the-counter remedies, including common cold or flu medicines. This review is necessary because those products could potentially interact with Bloodlet or the chemotherapy agent it is being used to support.

Q: Can Bloodlet be split or crushed to make it easier to take?

A: Official patient guidance for the oral tablet explicitly states that the tablet must be swallowed whole. The guidance typically advises against chewing, crushing, or breaking the tablet to ensure proper delivery of the medicine.

How should Bloodlet be stored and disposed of?

Bloodlet (Leucovorin Calcium) must be stored and disposed of according to specific regulatory requirements that differ by formulation.

Storage Conditions

Both the oral tablets and the unopened injectable vials must be stored at Controlled Room Temperature (20 C to 25 C). The product must not be frozen. Oral tablets must be kept in the original container, tightly closed, and protected from moisture. Injectable vials must be protected from light by retaining them in the outer carton.

Stability and Handling

The diluted injectable solution has a limited stability period and must be used immediately or within a few days if stored under refrigeration. Any partially used single-dose vials must be discarded. The product must be stored out of the reach and sight of children.

Disposal Instructions

All unused or expired product must be disposed of according to local pharmaceutical waste procedures. The medicine must not be thrown into household waste or wastewater. The injectable solution is considered hazardous medicinal product waste and must be handled according to specific national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bloodlet found in:

A-Z Index: